Top-down versus step-up treatment for pediatric ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial compares two treatment approaches for children newly diagnosed with ulcerative colitis: starting with stronger medicines right away versus beginning simpler and stepping up if needed. It may help your child learn which strategy controls symptoms better with fewer flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is 6 to 18 years old
- Your child has newly diagnosed ulcerative colitis
- Your child currently has moderate to severe disease activity
- Your child does NOT have only mild disease activity
- Your child has not already been treated with steroid medicines for ulcerative colitis
- Your child has not already been treated with biologic medicines for ulcerative colitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study compares two biologic medicines, vedolizumab and infliximab, to see which works better for children with moderate to severe ulcerative colitis. It aims to find a more effective treatment to reduce symptoms and improve quality of life.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This trial studies whether budesonide extended-release tablets are safe and effective for improving symptoms in children ages 5–17 with active, mild to moderate ulcerative colitis. It also measures how the medicine moves through the body.
This trial studies whether transferring healthy stool bacteria into the gut (fecal microbiota transplantation, or FMT) can improve symptoms in children with ulcerative colitis. It may help by changing gut bacteria, especially for children who are newly diagnosed or who didn’t respond to standard treatments.
This study monitors levels of certain medications (infliximab, adalimumab, vedolizumab, ustekinumab) in children with inflammatory bowel disease to see if adjusting the dose helps them feel better. It aims to improve treatment outcomes.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.